ASCO 2022: A first-in-human phase I dose escalation of YH001 (CTLA-4 mAb) in combination with PD-1 mAb in patients with advanced solid tumors

ASCO 2022: A first-in-human phase I dose escalation of YH001 (CTLA-4 mAb) in combination with PD-1 mAb in patients with advanced solid tumors

YH001 is a humanized anti-hCTLA-4 IgG1 mAb that relieves CTLA-4-mediated immunosuppression, and thereby enhances the T-cell-mediated antitumor immune response. Pre-clinical data have shown potent anti-cancer activity when combined with anti-PD-1 mAb.

YH001 was well tolerated up to 4 mg/kg dose levels when combined with toripalimab and has shown encouraging antitumor activity in patients with advanced solid tumors. Clinical trial information: NCT04357756.

Share:

    Please fill out the form below to request a download of this poster

    WordPress Double Opt-in by Forge12